课题基金 / 基金详情

ADPKD Connective Tissue Disorder Link

ADPKD Connective Tissue Disorder Link
ADPKD 结缔组织疾病链接
批准号:
7230235
负责人:
ROBERT L BACALLAO
金额:
$14.71万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-05-01 至 2009-04-30
关键词:
AccountingAddressAffectAffinityAnabolismAntibodiesArchitectureAutosomal Dominant Polycystic KidneyAutosomal Recessive Polycystic KidneyBindingBiogenesisBlood VesselsBuffersCardiovascular AbnormalitiesCell ProliferationCellsChromosomes, Human, Pair 15Chromosomes, Human, Pair 16Coculture TechniquesCodeConditionCongenital Heart DefectsConnective Tissue DiseasesCystCystic kidneyDataDialysis procedureDiseaseEctopic ExpressionElastinElectron MicroscopyEmployee StrikesEpithelialEpithelial Cell ProliferationEpithelial CellsExtracellular MatrixExtracellular Matrix ProteinsFBN1FamilyFibroblastsGenesGeneticGenomicsGoalsGrowthGuanidinium ChlorideHigher Order Chromatin StructureHumanImmunoblottingImmunofluorescence ImmunologicImmunohistochemistryInheritedInvestigationKidneyKidney FailureKidney GlomerulusKnockout MiceLabelLaboratoriesLeadLens dislocationLinkLocalizedMaintenanceMarfan SyndromeMicrofibrilsModelingMolecularMorphogenesisMutationMyopiaNamesNormal tissue morphologyNumbersPathogenesisPatientsPatternPeptide antibodiesPhenotypePhysical DialysisPolycystic Kidney DiseasesPolymerase Chain ReactionProcessProtein BiosynthesisProteinsPublic HealthRattusRecombinantsRoleSourceStagingStructureSystemTestingTissuesTranscriptTriton X100Tubular formationTunica MediaUnited StatesUrsidae FamilyVascular Permeabilitiescell growthcell typeextracellularfetalfibrillin-2gene cloninghuman microfibrillar-associated protein 2interestinterstitialmembermicrofibrillar proteinnephrogenesisnovelprotein expressionscoliosissizesubcutaneous

项目摘要

项目成果

ROBERT L BACALLAO的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): We have discovered a novel microfibril protein, named vascular matrix protein (VMP) which is extensively expressed in the media of large to medium sized blood vessels. Our evidence indicates that this protein is an alternative transcript arising from the PKD1 locus, the gene that codes for. Several lines of evidence support the conclusion that VMP is a component of matrix microfibrils. Extraction of VMP from tissue requires conditions similar to that described for other microfibril components such as fibrillin 1, 2, microfibril associated glycoprotein and elastin. VMP co-localized with fibrillin-1, fibrillin-2, elastin and microfibril associated glycoprotein (MAGP-1) as determined by immunohistochemistry and electron microscopy. Tissue etching with 6 M guanidinium chloride optimizes immunofluorescence labeling of tissue with anti-VMP. Discovery of VMP may account for the extra-renal manifestations of ADPKD which bears similarities to connective tissue disorders. Mutations in VMP may also account for the description of 2 families with ADPKD and connective tissue disorders. Strikingly these families phenotypically resemble a Marfan phenotype, yet their overlap connective tissue disorder linked to the PKD1 locus on chromosome 16 (Somlo et al., JASN, vol 4, 1371-8, 1993). Identification of another transcript encoded which codes for an extracellular matrix microfibril may also explain the finding that PKD1 knockout mice, generated by deletions from the 3' end of PKD1, have a fetal lethal phenotype due to increased vascular permeability, cardiac defects and subcutaneous hemorhages (Kim et al., PNAS, vol 97, 1731-35, 2000). VMP is ectopically expressed in the renal interstitium only in the setting of kidney cyst formation. This suggests that VMP expression is linked to epithelial growth abnormalities that lead to cyst formation. The goals of this proposal are to unambiguously identify the gene that codes for VMP, determine the biogenesis of VMP and examine its potential role in cystogenesis or nephrogenesis. RELEVANCE TO PUBLIC HEALTH-Polycystic kidney disease is the most common genetic cause of renal failure in the United States. Better understanding of the disease process will lead to therapies that halt progression of renal failure thereby decreasing the number of patients on dialysis.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1002/prca.200780140
发表时间: 2008-07-01
期刊: PROTEOMICS CLINICAL APPLICATIONS
影响因子: 2
作者: [Lai, Xianyin, Bacalla, Robert L., Blazer-Yost, Bonnie L., Hong, David, Mason, Stephen B., Witzmann, Frank A.]
通讯作者: Witzmann, Frank A.
Mitochondria Functions Modified by Sulfotransferase 1C2
  • 批准号:
    10230976
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2020
  • 负责人:
    ROBERT L BACALLAO
  • 依托单位:
Mitochondria Functions Modified by Sulfotransferase 1C2
  • 批准号:
    10664935
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2020
  • 负责人:
    ROBERT L BACALLAO
  • 依托单位:
Mitochondria Functions Modified by Sulfotransferase 1C2
  • 批准号:
    10016916
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2020
  • 负责人:
    ROBERT L BACALLAO
  • 依托单位:
Endogenous Mitochondria Resistance to Acute Kidney Injury
  • 批准号:
    8971622
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2014
  • 负责人:
    ROBERT L BACALLAO
  • 依托单位:
海外基金